| Reference number |
2025-00299 |
| Coordinator |
MyCural Therapeutics AB |
| Funding from Vinnova |
SEK 0 |
| Project duration |
March 2025 - April 2025
|
| Status |
Completed |
| Venture |
Global cooperation 2025 |
Important results from the project
Yes, the goals were met. We established and deepened relationships with potential partners and investors, which resulted in increased interest from a pharmaceutical company and several private investors. Through our participation in Swiss Nordic Bio-konferensen, we gained access to a valuable network, which opens up opportunities for investments and collaborations in method development and drug development in the longer term.
Expected long term effects
The project is expected to have long-term effects by establishing strong partnerships and networks within both the pharmaceutical and biotechnology sectors. This will facilitate future investments and collaborations, which are crucial to take MyCural to clinical stages and develop a drug candidate. In the longer term, the project can also generate new opportunities for method development and strengthen the company´s position in the market, contributing to sustainable growth.
Approach and implementation
MyCural participated in strategic conferences and presented the company to potential partners and investors. We met with two pharma companies, one of which showed interest, as well as several family offices and private investors. Through these interactions, important contacts and a network were established in Switzerland, which may lead to future collaborations and investments. The focus was on creating long-term relationships and securing capital for the next development phase.
External links
The project description has been provided by the project members themselves and the text has not been looked at by our editors.
